Since the late 2000’s the FDA has received thousands of complaints related to complications stemming from transvaginal placement of surgical mesh. Transvaginal mesh has traditionally been used to treat pelvic organ prolapse (POP) and stress urinary incontinence (SUI) in women. In some cases, the mesh can begin to erode through the vaginal walls or other organs within weeks or months after surgery.

These transvaginal mesh injuries can hinder any number of activities, including sitting, walking and sexual intercourse. The physical and emotional harm can affect women’s work, relationships and daily activities. Some experts argue that the surgical mesh is not safe for transvaginal placement and was not properly tested before being implanted into women.